Developing Optimized Treatment Plans for Patients with Dyslipidemia in the Era of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapeutics

James A. Underberg, Michael Blaha, Elizabeth J. Jackson, Peter H. Jones

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Developing Optimized Treatment Plans for Patients with Dyslipidemia in the Era of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapeutics'. Together they form a unique fingerprint.

Medicine & Life Sciences